Intravenous LOLA Dosing for Grade III Hepatic Encephalopathy
For Grade III hepatic encephalopathy, administer intravenous L-ornithine-L-aspartate (LOLA) at 30 g/day as a continuous infusion over 24 hours for 5 days, always in combination with lactulose (and rifaximin if available). 1
Recommended Dosing Protocol
The 2020 KASL Clinical Practice Guidelines explicitly recommend 30 g/day intravenous LOLA for overt hepatic encephalopathy 1. This dose should be:
- Administered as continuous IV infusion over 24 hours (not intermittent boluses)
- Duration: 5 consecutive days as standard treatment course
- Always combined with standard therapy (lactulose ± rifaximin), never as monotherapy
Administration Details
Preparation and infusion:
- Dissolve 30 g LOLA in appropriate IV solution (typically 250-500 mL)
- Administer as continuous infusion to maintain steady ammonia-lowering effect
- Monitor for mild gastrointestinal disturbances (occurs in ~5% of patients) 2
Evidence Supporting This Approach
The guideline recommendation is strongly supported by high-quality RCT data specifically in severe (Grade III-IV) hepatic encephalopathy. The most recent and highest quality study 3 demonstrated that in Grade III-IV HE, LOLA 30 g/day as continuous infusion combined with lactulose and rifaximin resulted in:
- 92.5% improvement rate vs 66% with placebo (p<0.001)
- Faster recovery time: 2.70 days vs 3.00 days (p=0.03)
- Dramatically lower 28-day mortality: 16.4% vs 41.8% (p=0.001)
This 2022 study 3 specifically addressed Grade III-IV patients and showed mortality benefit—the most critical outcome—making it the strongest evidence for this population.
Important Clinical Considerations
Why Grade III matters: Grade III HE (West-Haven criteria) represents severe encephalopathy where patients cannot take oral medications reliably. The guidelines 1 specifically note that oral rifaximin has limited utility in Grade III or higher "because of the need for oral administration," making IV LOLA particularly valuable in this setting.
Mechanism of benefit: LOLA provides ornithine and aspartate as substrates for ammonia metabolism to urea and glutamine 1. The continuous infusion maintains steady substrate availability for ammonia detoxification.
Common pitfall: Do not use LOLA as monotherapy. Multiple studies 4, 3 demonstrate efficacy only when combined with standard lactulose-based therapy. The guidelines 1 do not support LOLA alone.
Alternative Dosing from Older Literature
Earlier studies used 20 g/day over 4 hours 2, 5, but current guidelines 1 recommend the higher 30 g/day dose based on more recent evidence showing superior outcomes 4, 3. The 30 g dose as continuous 24-hour infusion is now standard.
Duration flexibility: While 5 days is standard, treatment should continue until clinical improvement is noted. One study 6 used 7-day courses with good safety profile.
Oral LOLA is NOT Recommended
The guidelines 1, 7 explicitly state that oral LOLA is ineffective for overt HE and requires further study. Only intravenous formulation should be used for Grade III encephalopathy.